Literature DB >> 26132690

Functional versus syndromal recovery in patients with major depressive disorder and bipolar disorder.

Trijntje Y G van der Voort1, Adrie Seldenrijk, Berno van Meijel, Peter J J Goossens, Aartjan T F Beekman, Brenda W J H Penninx, Ralph W Kupka.   

Abstract

OBJECTIVE: Many patients with major depressive disorder (MDD) or bipolar disorder (BD) experience impairments in daily life. We investigated whether patients with single-episode MDD (MDD-s), recurrent MDD (MDD-r), and BD differ in functional impairments, whether time since last episode (syndromal state, in 4 categories) contributes to impairment, whether this association is moderated by diagnosis, and the role of depressive symptoms.
METHOD: Data were derived from 1,664 participants in the Netherlands Study of Depression and Anxiety (MDD-s, n = 483; MDD-r, n = 1,063; BD, n = 118), from 2006 into 2009. In additional analyses, 530 healthy controls were included. DSM-IV-TR diagnosis and information about syndromal state were based on the Composite International Diagnostic Interview. Psychosocial impairment was assessed with the World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0). Adjusted associations between diagnosis, syndromal state, impairment, and depression severity were investigated.
RESULTS: Syndromal state not being taken into account, patients with BD experienced more functional impairment than patients with MDD-s or with MDD-r, and in all diagnostic groups, impairments decreased with increasing time since last episode. However, impact of syndromal state on functioning showed a different course between diagnostic groups (mean [SD] WHODAS score: current: MDD-s 30.8 [2.8], MDD-r 32.7 [0.9], BD 37.7 [2.1], P = .07; recently remitted: MDD-s 21.7 [3.5], MDD-r 24.0 [1.2], BD 22.1[3.2], P = .7; remitted: MDD-s 10.6 [3.7], MDD-r 21.6 [1.4], BD 19.2 [4.4], P = .02; remitted > 1 year: MDD-s 13.3 [0.6], MDD-r 14.7 [0.5], BD 17.1 [2.2], P = .8). Depression severity accounted for these differences. Moreover, functioning in all remitted patients remained impaired when compared to that in healthy controls.
CONCLUSION: Functional recovery may take up to 1 year after syndromal remission in recurrent depressive and bipolar disorder, mainly due to residual depressive symptoms, emphasizing the need for prolonged continuation treatment. © Copyright 2015 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Year:  2015        PMID: 26132690     DOI: 10.4088/JCP.14m09548

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  16 in total

Review 1.  Treatment of Functional Impairment in Patients with Bipolar Disorder.

Authors:  Jose Sanchez-Moreno; Anabel Martinez-Aran; Eduard Vieta
Journal:  Curr Psychiatry Rep       Date:  2017-01       Impact factor: 5.285

Review 2.  Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 1. Disease Burden and Principles of Care.

Authors:  Raymond W Lam; Diane McIntosh; JianLi Wang; Murray W Enns; Theo Kolivakis; Erin E Michalak; Jitender Sareen; Wei-Yi Song; Sidney H Kennedy; Glenda M MacQueen; Roumen V Milev; Sagar V Parikh; Arun V Ravindran
Journal:  Can J Psychiatry       Date:  2016-08-02       Impact factor: 4.356

3.  An Open-Label Pilot Study of Combined Augmentation With Creatine Monohydrate and 5-Hydroxytryptophan for Selective Serotonin Reuptake Inhibitor- or Serotonin-Norepinephrine Reuptake Inhibitor-Resistant Depression in Adult Women.

Authors:  Brent M Kious; Hana Sabic; Young-Hoon Sung; Douglas G Kondo; Perry Renshaw
Journal:  J Clin Psychopharmacol       Date:  2017-10       Impact factor: 3.153

Review 4.  A Lifespan Model of Interference Resolution and Inhibitory Control: Risk for Depression and Changes with Illness Progression.

Authors:  Katie L Bessette; Aimee J Karstens; Natania A Crane; Amy T Peters; Jonathan P Stange; Kathleen H Elverman; Sarah Shizuko Morimoto; Sara L Weisenbach; Scott A Langenecker
Journal:  Neuropsychol Rev       Date:  2020-01-15       Impact factor: 7.444

5.  Using WHODAS 2.0 to Assess Functional Impairment in People with Depression: Should Employment Receive More Attention?

Authors:  Yu-Chen Chiang; Tsan-Hon Liou; Hsin-Chien Lee; Reuben Escorpizo
Journal:  Int J Environ Res Public Health       Date:  2021-04-25       Impact factor: 3.390

6.  The polygenic risk for bipolar disorder influences brain regional function relating to visual and default state processing of emotional information.

Authors:  Danai Dima; Simone de Jong; Gerome Breen; Sophia Frangou
Journal:  Neuroimage Clin       Date:  2016-11-01       Impact factor: 4.881

7.  Symptomatic and functional recovery in depression in later life.

Authors:  Rose M Collard; Sanne Wassink-Vossen; Aart H Schene; Paul Naarding; Peter Verhaak; Richard C Oude Voshaar; Hannie C Comijs
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2018-06-19       Impact factor: 4.328

8.  Effects on health-related quality of life in patients treated with lurasidone for bipolar depression: results from two placebo controlled bipolar depression trials.

Authors:  Krithika Rajagopalan; Elizabeth Dansie Bacci; Daisy Ng-Mak; Kathy Wyrwich; Andrei Pikalov; Antony Loebel
Journal:  BMC Psychiatry       Date:  2016-05-23       Impact factor: 3.630

9.  Stability of remission rates in a 3-year follow-up of naturalistic treated depressed inpatients.

Authors:  Florian Seemüller; Michael Obermeier; Rebecca Schennach; Michael Bauer; Mazda Adli; Peter Brieger; Gerd Laux; Michael Riedel; Peter Falkai; Hans-Jürgen Möller
Journal:  BMC Psychiatry       Date:  2016-05-20       Impact factor: 3.630

10.  The Relationship between Symptom Relief and Psychosocial Functional Improvement during Acute Electroconvulsive Therapy for Patients with Major Depressive Disorder.

Authors:  Ching-Hua Lin; Wei-Cheng Yang
Journal:  Int J Neuropsychopharmacol       Date:  2017-07-01       Impact factor: 5.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.